GNCA - Genocea (GNCA) shares rise 47% after reporting benefits of ATLAS platform in cancer study

Genocea Biosciences (GNCA) soars 47% premarket after highlighting the advantages of neoantigen identification with the ATLAS platform in a journal Cancer Discovery.The publication shows that ATLAS zeroes in on tumor mutations that are either neoantigens that activate anti-tumor responses or inhibitory antigens (Inhibigens) that are targets of pro-tumor responses, in both CD8+ (killer) and CD4+ (helper) T cells.This breakthrough improves neoantigen immunotherapies by potentially ensuring they are targeting the right neoantigens and excluding Inhibigens. Preclinical results demonstrate the biological relevance of Inhibigens. In the B16F10 mouse melanoma model, T cell responses to Inhibigens stifle protective anti-tumor immune responses in vivo.ATLAS-identified Inhibigens on their own, or when combined in a vaccine formulation, led to tumor growth that was comparable to, or in some cases surpassed, tumor growth in control animals.In contrast, when an ATLAS-identified anti-tumor neoantigen was added to the same formulation, tumor growth was either significantly delayed or completely abrogated. “Our research in both humans

For further details see:

Genocea (GNCA) shares rise 47% after reporting benefits of ATLAS platform in cancer study